Defactinib
RAS Pathway-Driven Cancers (in combination)
Phase 1/2Active
Key Facts
Indication
RAS Pathway-Driven Cancers (in combination)
Phase
Phase 1/2
Status
Active
Company
About Verastem Oncology
Verastem Oncology is on a mission to ensure no cancer patient runs out of treatment options by developing novel therapies for RAS/MAPK pathway-driven cancers, which are implicated in nearly a third of all cancers. The company achieved a significant milestone with the FDA approval of its combination therapy for KRAS-mutant recurrent low-grade serous ovarian cancer. Its clinical strategy is powered by a robust portfolio of ongoing trials and strategic collaborations, focusing on avutometinib as a backbone therapy in combination with agents like the FAK inhibitor defactinib to block compensatory pathways and drive deeper, more durable responses.
View full company profile